HELP vs IVA: fair value comparison
Cybin D/B/A Helus Pharma and Inventiva S.A. · Updated 2026-10-19
HELP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IVA reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, HELP currently ranks higher by quality score.
| HELP | IVA | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $10.55 | $3.46 |
| 12-month range | $3.87–$14.02 | $2.87–$7.15 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #293 of 301 Healthcare | #294 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | — | Moderate |
| Margin trend | — | Contracting |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: HELP fair value analysis · IVA fair value analysis